FDA Brief

Warning letters Drugs

FDA warning letter to

GFA Production Xiamen Co., Ltd.

High riskIssued Jun 13, 2024Posted Jun 18, 2024Center for Drug Evaluation and Research | CDER

GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.

What happened

FDA inspected GFA Production Xiamen’s drug manufacturing facility in Xiamen from December 4 to 8, 2023. The inspection found missing or inadequate process validation, cleaning validation, equipment alarm monitoring, HPLC data records, and microbiological laboratory controls. FDA also noted a prior voluntary recall of EasyCare First Aid AfterBurn Cream due to microbiological contamination and two import alerts.

What FDA found

  1. The firm did not provide adequate data to show its drug manufacturing processes were validated or to justify its process performance qualification reports.

    21 CFR 211.100(a) and 211.100(b)
  2. The firm did not adequately validate cleaning of equipment used to manufacture its drugs.

    21 CFR 211.100(a) and 211.100(b)
  3. The firm did not monitor and document equipment alarms and disabled stability chamber alarms.

    21 CFR 211.100(a) and 211.100(b)
  4. The firm’s in-house HPLC testing records lacked audit trails and method validation reports.

    21 CFR 211.194(a)
  5. The firm’s microbiological laboratory methods were inadequate, and it did not identify microorganisms from incubated plates.

    21 CFR 211.160(a)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions and remediation plans, including risk assessments, process and cleaning validation, laboratory controls, and testing of retain samples. If it resumes manufacturing for the U.S. market, it must notify FDA first and use a qualified consultant.

Who should pay attention

  • brands that buy drugs or first aid kits from this contract manufacturer
  • distributors and retailers of EasyCare first aid products
  • companies relying on GFA for outsourced drug manufacturing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk